

Clinical Study Protocol**ASP-OP3-1****EudraCT No
2017-004864-37**

A Multinational, Phase 3, Double-blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of Ovestin in the Treatment of Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women.

This study was submitted to authorities, however the study was stopped without any patients being recruited, therefore no report was created.

Michelle Singleton

Group Operations Clinical and Pharmacovigilance Manager
Aspen Pharmacare Holdings Limited
Company Registration Number 1985/002935/06
Building 12, Healthcare Park, Woodlands Drive, Woodmead, Sandton, Gauteng, 2191, South Africa

P.O.Box: 25125, Gateway, Kwa-Zulu Natal, 4321, South Africa
Switchboard: +27 31 580 8600 : Direct Tel: +27 11 239 6524